TC BioPharm to Present at the Sequire Investor Summit
EDINBURGH, Scotland, Jan. 18, 2024 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.
Related news for (TCBP)
- Don’t Miss Out: MoBot’s Latest Stock Updates 02/13/25 08:00 AM
- MoBot’s Movers
- TCBP Plans to Acquire NK Platform Technologies
- 24/7 Market News Snapshot 9 Feb 2024- (NASDAQ:CLSK), (NASDAQ:NSTG), (NASDAQ:TOP), (NASDAQ:TCBP), (NASDAQ:SUNW), (NASDAQ:INBS
- TC BioPharm Chief Executive Officer, Bryan Kobel Featured on ‘The Big Biz Show’